Caitlin John’s Jazz Pharmaceuticals JAZZ Stock Holding History

Caitlin John’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$567	Hold	3	–	–	﹤0.01%	846
2025 Q4	$510	Hold	3	–	–	﹤0.01%	852
2025 Q3	$395	Buy	+3	New	+$360	﹤0.01%	832
2025 Q1	–	Sell	-3	Closed	-$369	–	471
2024 Q4	$369	Hold	3	–	–	﹤0.01%	798
2024 Q3	$383	Hold	3	–	–	﹤0.01%	790
2024 Q2	$320	Hold	3	–	–	﹤0.01%	792
2024 Q1	$361	Hold	3	–	–	﹤0.01%	820
2023 Q4	$369	Buy	+3	New	+$374	﹤0.01%	821

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Caitlin John's JAZZ Position: Q1 2026 in Review

Caitlin John held its Jazz Pharmaceuticals (JAZZ) position steady in Q1 2026 at 3 shares worth $567. The position accounts for ﹤0.01% of the portfolio, ranked #846.

Caitlin John first reported a position in JAZZ in Q4 2023 and has held it in 8 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Caitlin John held 3 shares of Jazz Pharmaceuticals worth $567 as of Q1 2026.
Caitlin John left its Jazz Pharmaceuticals share count unchanged in Q1 2026.
Jazz Pharmaceuticals made up ﹤0.01% of Caitlin John's portfolio in Q1 2026, its #846 holding.
Caitlin John first reported a position in Jazz Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Caitlin John's 13F filing for Q1 2026, filed 13 May 2026.